| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yosef Sarne, Raphael Mechoula. Cannabinoids: between neuroprotection and neurotoxicity. Current drug targets. CNS and neurological disorders. vol 4. issue 6. 2006-02-07. PMID:16375685. |
some of these mechanisms involve the activation of cb1 and cb2 cannabinoid receptors, while others are not dependent on them. |
2006-02-07 |
2023-08-12 |
Not clear |
| Nichola J Underdown, C Robin Hiley, William R For. Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. British journal of pharmacology. vol 146. issue 6. 2006-02-03. PMID:16158067. |
despite sensitivity to cb1 and cb2 receptor antagonists, the infarct-limiting action of anandamide was not mimicked by agonists selective for cb1 or cb2 receptors suggesting the involvement of a novel cannabinoid site of action. |
2006-02-03 |
2023-08-12 |
rat |
| Jenny Flygare, Kristin Gustafsson, Eva Kimby, Birger Christensson, Birgitta Sande. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS letters. vol 579. issue 30. 2006-01-23. PMID:16337199. |
we have earlier reported overexpression of the central and peripheral cannabinoid receptors cb1 and cb2 in mantle cell lymphoma (mcl), a b cell non-hodgkin lymphoma. |
2006-01-23 |
2023-08-12 |
Not clear |
| Adèle Thomas, Lesley A Stevenson, Kerrie N Wease, Martin R Price, Gemma Baillie, Ruth A Ross, Roger G Pertwe. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. British journal of pharmacology. vol 146. issue 7. 2006-01-20. PMID:16205722. |
evidence that the plant cannabinoid delta9-tetrahydrocannabivarin is a cannabinoid cb1 and cb2 receptor antagonist. |
2006-01-20 |
2023-08-12 |
mouse |
| U Schneider, J Seifert, M Karst, J Schlimme, K Cimander, K R Müller-Vah. [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders]. Der Nervenarzt. vol 76. issue 9. 2006-01-19. PMID:15776259. |
this is based on the discovery that cannabinoids act with specific receptors (cb1 and cb2). |
2006-01-19 |
2023-08-12 |
Not clear |
| S A Moore, G G Nomikos, A K Dickason-Chesterfield, D A Schober, J M Schaus, B-P Ying, Y-C Xu, L Phebus, R M A Simmons, D Li, S Iyengar, C C Felde. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proceedings of the National Academy of Sciences of the United States of America. vol 102. issue 49. 2006-01-18. PMID:16314570. |
delta9-tetrahydrocannabinol and endogenous cannabinoids (e.g., anandamide) initiate their agonist properties by stimulating the cannabinoid family of g protein-coupled receptors (cb1 and cb2). |
2006-01-18 |
2023-08-12 |
Not clear |
| Outi M H Salo, Katri H Raitio, Juha R Savinainen, Tapio Nevalainen, Maija Lahtela-Kakkonen, Jarmo T Laitinen, Tomi Järvinen, Antti Pos. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. Journal of medicinal chemistry. vol 48. issue 23. 2006-01-17. PMID:16279774. |
virtual screening of novel cb2 ligands using a comparative model of the human cannabinoid cb2 receptor. |
2006-01-17 |
2023-08-12 |
human |
| Antonella Brizzi, Vittorio Brizzi, Maria Grazia Cascio, Tiziana Bisogno, Rossella Sirianni, Vincenzo Di Marz. Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. Journal of medicinal chemistry. vol 48. issue 23. 2006-01-17. PMID:16279794. |
binding studies on cb1 and cb2 receptors, anandamide membrane transporter (amt), and fatty acid amide hydrolase (faah) showed that some of the newly developed compounds have high affinity and specificity for cannabinoid cb1 and cb2 receptors. |
2006-01-17 |
2023-08-12 |
Not clear |
| Birgit Kraft, Hans G Kres. Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. The Journal of pharmacology and experimental therapeutics. vol 315. issue 2. 2006-01-12. PMID:16055676. |
indirect cb2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. |
2006-01-12 |
2023-08-12 |
human |
| Jennifer L Shoemaker, Michael B Ruckle, Philip R Mayeux, Paul L Prathe. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. The Journal of pharmacology and experimental therapeutics. vol 315. issue 2. 2006-01-12. PMID:16081674. |
this study examined the ability of the endocannabinoids 2-arachidonoyl glycerol (2-ag) and noladin ether as well as the synthetic cannabinoid cp-55,940 [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol] to regulate three intracellular effectors via cb2 receptors in transfected chinese hamster ovary cells. |
2006-01-12 |
2023-08-12 |
Not clear |
| Jennifer L Shoemaker, Michael B Ruckle, Philip R Mayeux, Paul L Prathe. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. The Journal of pharmacology and experimental therapeutics. vol 315. issue 2. 2006-01-12. PMID:16081674. |
this suggests that 2-ag stimulates ca(2+)-transients by binding to sites on cb2 receptors distinct from those occupied by am630 and the other cannabinoids examined. |
2006-01-12 |
2023-08-12 |
Not clear |
| Jennifer L Shoemaker, Michael B Ruckle, Philip R Mayeux, Paul L Prathe. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. The Journal of pharmacology and experimental therapeutics. vol 315. issue 2. 2006-01-12. PMID:16081674. |
in summary, cannabinoid agonists distinctly bind to cb2 receptors and display different rank order of potencies and fractional receptor occupancies for regulation of intracellular effectors. |
2006-01-12 |
2023-08-12 |
Not clear |
| P M Beardsley, B F Thoma. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148435. |
since the discovery of the cannabinoid cb1 receptor (cb1r) in 1988, and subsequently of the cb2 receptor (cb2r) in 1993, there has been an exponential growth of research investigating the functions of the endocannabinoid system. |
2006-01-09 |
2023-08-12 |
Not clear |
| Billy R Marti. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life sciences. vol 77. issue 14. 2006-01-05. PMID:15949820. |
the discovery of the endocannabinoid system that contains two receptor subtypes, cb1 and cb2, associated signaling pathways, endocannabinoids (anandamide and 2-arachidonoylglycerol) and their synthetic and degradative pathways has provided a means of systematically evaluating the mechanism of cannabinoid tolerance. |
2006-01-05 |
2023-08-12 |
Not clear |
| Sumner Burstei. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life sciences. vol 77. issue 14. 2006-01-05. PMID:16005906. |
an increasing number of cannabinoid actions are being reported that do not appear to be mediated by either cb1 or cb2, the known cannabinoid receptors. |
2006-01-05 |
2023-08-12 |
human |
| Niamh M Curran, Bryan D Griffin, Daniel O'Toole, Kevin J Brady, Stephen N Fitzgerald, Paul N Moynag. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. The Journal of biological chemistry. vol 280. issue 43. 2006-01-04. PMID:16105834. |
this inhibition is not mediated via the cb1 or cb2 cannabinoid receptors, because their selective antagonists and pertussis toxin failed to affect the inhibitory effects of r(+)win 55,212-2. |
2006-01-04 |
2023-08-12 |
human |
| Mario van der Stelt, Vincenzo Di Marz. Cannabinoid receptors and their role in neuroprotection. Neuromolecular medicine. vol 7. issue 1-2. 2005-12-08. PMID:16052037. |
two g protein-coupled receptors for marijuana's psychoactive component, delta9-tetrahydrocannabinol, have been cloned to date, the cannabinoid cb1 and cb2 receptors. |
2005-12-08 |
2023-08-12 |
Not clear |
| Andrew S Yates, Stephen W Doughty, David A Kendall, Barrie Kella. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorganic & medicinal chemistry letters. vol 15. issue 16. 2005-12-05. PMID:15993070. |
chemical modification of the naphthoyl 3-position of jwh-015: in search of a fluorescent probe to the cannabinoid cb2 receptor. |
2005-12-05 |
2023-08-12 |
Not clear |
| Andrew S Yates, Stephen W Doughty, David A Kendall, Barrie Kella. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorganic & medicinal chemistry letters. vol 15. issue 16. 2005-12-05. PMID:15993070. |
in silico modelling was used to guide the positioning of the fluorescent dye nbd-f on the cannabinoid cb2 receptor agonist jwh-015. |
2005-12-05 |
2023-08-12 |
Not clear |
| Andrew S Yates, Stephen W Doughty, David A Kendall, Barrie Kella. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorganic & medicinal chemistry letters. vol 15. issue 16. 2005-12-05. PMID:15993070. |
while the ultimate fluorescent conjugate lost extensive binding affinity to the cannabinoid cb2 receptor, affinity and efficacy studies on the naphthoyl 3-position modified precursor molecules have provided new insight into structure-activity relationships associated with this position. |
2005-12-05 |
2023-08-12 |
Not clear |